There is an urgency to develop clinically useful agents that will be able to inhibit the action of cathepsin B. Our research demonstrated that MM131 at a dose of 3 μM significantly reduced cathepsin B concentrations in DLD-1 and HT-29 colon cancer cells. Here, CTSB is linked to colonic neoplasm.